• Cadrenal plans to file an FDA Rare Pediatric Disease Designation request for tecarfarin in Kawasaki disease patients needing chronic anticoagulation.
• A granted designation could set up eligibility for a Priority Review Voucher if tecarfarin later wins FDA approval for the indication.
• Recent open-market valuations for pediatric Priority Review Vouchers have ranged from $180 million to $205 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-069902), on June 18, 2026, and is solely responsible for the information contained therein.